CD160 and neoplasm: Using unrelated tumor-associated antigens such as E7 of human papilloma virus (HPV)-16 or a series of melanoma-associated epitopes in tumor-bearing young mice, we confirmed that gD-mediated BTLA/CD160 blockade increases CD8+ T cell responses, especially to subdominant epitopes, renders CD8+ T cells less susceptible to exhaustion within a tumor micro-environment and improves the T cells’ ability to reduce tumor progression [9,10].